This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Citalopram for Compulsive Shopping Disorder: An Open-Label Study Followed by Double-Blind Discontinuation

Lorrin M. Koran, MD; Helen W. Chuong, MS; Kim D. Bullock, MD; and S. Christine Smith, MD

Published: July 15, 2003

Article Abstract

Background: Open-label trials suggested that fluvoxamine and citalopram may be effective for compulsive shopping disorder, but 2 double-blind fluvoxamine trials failed to confirm this. To test the hypothesis that citalopram is a safe, effective treatment for this disorder, we conducted a 7-week, open-label trial followed by a 9-week, double-blind, placebo-controlled discontinuation trial.

Method: From Jan. 2001 to Jan. 2002, we enrolled adult outpatients meeting diagnostic criteria suggested in a prior study for compulsive shopping disorder and having a score of >= 17 on the Yale-Brown Obsessive Compulsive Scale-Shopping Version (YBOCS-SV). Open-label citalopram was started at 20 mg/day and increased, absent marked response and limiting side effects, to 60 mg/day. Responders (subjects rated “much improved” or “very much improved” on the Clinical Global Impressions-Improvement scale [CGI-I] and having a >= 50% decrease in YBOCS-SV score) were randomized to double-blind citalopram treatment at the week 7 dose or placebo for 9 weeks.

Results: We enrolled 24 subjects (23 women and 1 man). Mean ± SD YBOCS-SV scores decreased significantly from 24.3 ± 4.6 at baseline to 8.2 ± 8.1 at week 7 (Wilcoxon signed rank: z = 4.20, p = 17 and “minimally improved” or less on the CGI-I) compared with none of 7 randomized to continue taking citalopram (Fisher exact test p = .019).

Conclusion: Citalopram appears to be a safe and effective treatment for compulsive shopping disorder. Further trials of citalopram and other selective serotonin reuptake inhibitors are warranted.

Volume: 64

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF